The current study,The Phase 2b study titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease” (“CUPID Phase 2b Trial”) is a multinational, multicenter, double-blind, placebo-controlled, randomized study currently recruiting subjects in the United States and in Europe. Results are anticipated in the first half of 2015. Please visit the ClincalTrials.gov website for more information, or call Celladon Corporation 1-858-366-4288.
The phase 2 CUPID Trial successfully met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR® versus placebo. Additionally, 12 months after receiving a single infusion of MYDICAR®, patients treated with the highest dose versus placebo had an 88 percent reduction of major cardiovascular events* such as death, need for left ventricular assist device (LVAD) or cardiac transplant, and number of heart failure-related hospitalizations.
Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR®, a potential breakthrough for the treatment of severe heart failure. MYDICAR is designed to restore a critical enzyme necessary for the heart to pump more efficiently. Read More
Celladon is dedicated to the treatment of cardiac diseases through the use of new technologies in molecular cardiology. Celladon’s products are first-in-class drugs that target the key enzyme deficiency in severe heart failure, SERCA2a. A major underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal intracellular calcium cycling and poor contractility. Our research shows that recombinant adeno-associated viral (AAV) vectors are ideal for restoring SERCA2a enzyme production via gene transfer to cardiac muscle cells.
Click on the links below for Celladon's Product Overview.